New York State Common Retirement Fund

New York State Common Retirement Fund’s SAB Biotherapeutics SABS Stock Holding History

New York State Common Retirement Fund’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.3K	Buy	+12,900	New	+$48K	﹤0.01%	3010

Other funds holding SABS

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

New York State Common Retirement Fund's SABS Position: Q2 2026 in Review

New York State Common Retirement Fund opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 12,900 shares worth $50.3K. The stake represents ﹤0.01% of the portfolio and ranks #3010 among its holdings.

11 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

New York State Common Retirement Fund held 12,900 shares of SAB Biotherapeutics worth $50.3K as of Q2 2026.
SAB Biotherapeutics was a new New York State Common Retirement Fund position in Q2 2026.
SAB Biotherapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #3010 holding.
11 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.